Gephyrin and CYP2C9 Genetic Polymorphisms in Patients with Pharmacoresistant Epilepsy

References

• Alexopoulos AV. Pharmacoresistant epilepsy: definition and explanation. Epileptology. 2013;1(1):38–42. doi:10.1016/j.epilep.2013.01.001
   Google Scholar
• Fountain NB, Van Ness PC, Swain-Eng R, Tonn S, Bever CT Jr; American Academy of Neurology Epilepsy Measure Development Panel and the American Medical Association-Convened Physician Consortium for Performance Improvement Independent Measure Development Process. Quality improvement in neurology: AAN epilepsy quality measures: report of the quality measurement and reporting subcommittee of the American Academy of neurology. Neurology. 2011;76(1):94–99. doi:10.1212/WNL.0b013e318203e9d1
   Web of Science ®Google Scholar
• Tang F, Hartz AMS, Bauer B. Drug-resistant epilepsy: multiple hypotheses, few answers. Front Neurol. 2017;8:301. doi:10.3389/fneur.2017.00301
   PubMed Web of Science ®Google Scholar
• Berg AT, Kelly MM. Defining intractability: comparisons among published definitions. Epilepsia. 2006;47(2):431–436. doi:10.1111/j.1528-1167.2006.00440.x
   Web of Science ®Google Scholar
• Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010;51(6):1069–1077. doi:10.1111/j.1528-1167.2009.02397.x
   PubMed Web of Science ®Google Scholar
• Farghaly WM, El-Tallawy HN, Rageh TA, et al. Epidemiology of uncontrolled epilepsy in the Al-Kharga District, New Valley, Egypt. Seizure. 2013;22(8):611–616. doi:10.1016/j.seizure.2013.04.010
   Web of Science ®Google Scholar
• Balestrini S, Sisodiya SM. Pharmacogenomics in epilepsy. Neurosci Lett. 2018;667:27–39. doi:10.1016/j.neulet.2017.01.014
   PubMed Web of Science ®Google Scholar
• Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol. 2005;45(1):477–494. doi:10.1146/annurev.pharmtox.45.120403.095821
   Web of Science ®Google Scholar
• Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002;12(3):251–263. doi:10.1097/00008571-200204000-00010
   PubMedGoogle Scholar
• Arici M, Özhan G. CYP2C9, CYPC19 and CYP2D6 gene profiles and gene susceptibility to drug response and toxicity in Turkish population. Saudi Pharm J. 2017;25(3):376–380. doi:10.1016/j.jsps.2016.09.003
   Web of Science ®Google Scholar
• Pirmohamed M, Park BK. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology. 2003;192(1):23–32. doi:10.1016/s0300-483x(03)00247-6
   PubMed Web of Science ®Google Scholar
• Naraharisetti SB, Lin YS, Rieder MJ, et al. Human liver expression of CYP2C8: gender, age, and genotype effects. Drug Metab Dispos. 2010;38(6):889–893. doi:10.1124/dmd.109.031542
   Web of Science ®Google Scholar
• Silvado CE, Terra VC, Twardowschy CA. CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment. Pharmgenomics Pers Med. 2018;11:51–58. doi:10.2147/PGPM.S108113
   PubMed Web of Science ®Google Scholar
• Lopez-Garcia MA, Feria-Romero IA, Fernando-Serrano H, Escalante-Santiago D, Grijalva I, Orozco-Suarez S. Genetic polymorphisms associated with antiepileptic metabolism. Front Biosci (Elite Ed). 2014;6(2):377–386. doi:10.2741/713
   Google Scholar
• Depondt C, Godard P, Espel RS, Da Cruz AL, Lienard P, Pandolfo M. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur J Neurol. 2011;18(9):1159–1164. doi:10.1111/j.1468-1331.2011.03361.x
   PubMed Web of Science ®Google Scholar
• Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA. 2014;312(5):525–534. doi:10.1001/jama.2014.7859
   PubMed Web of Science ®Google Scholar
• Petrini EM, Ravasenga T, Hausrat TJ, et al. Synaptic recruitment of gephyrin regulates surface GABAA receptor dynamics for the expression of inhibitory LTP. Nat Commun. 2014;5(1):3921. doi:10.1038/ncomms4921
   Web of Science ®Google Scholar
• Choii G, Ko J. Gephyrin: a central GABAergic synapse organizer. Exp Mol Med. 2015;47(4):e158. doi:10.1038/emm.2015.5
   Web of Science ®Google Scholar
• Kamdar KP, Shelton ME, Finnerty V. The Drosophila molybdenum cofactor gene cinnamon is homologous to three Escherichia coli cofactor proteins and to the rat protein gephyrin. Genetics. 1994;137(3):791–801. doi:10.1093/genetics/137.3.791
   PubMed Web of Science ®Google Scholar
• Dejanovic B, Djémié T, Grünewald N, et al. Simultaneous impairment of neuronal and metabolic function of mutated gephyrin in a patient with epileptic encephalopathy. EMBO Mol Med. 2015;7(12):1580–1594. doi:10.15252/emmm.201505323
   Web of Science ®Google Scholar
• Giussani G, Canelli V, Bianchi E, et al. A population-based study of active and drug-resistant epilepsies in Northern Italy. Epilepsy Behav. 2016;55:30–37. doi:10.1016/j.yebeh.2015.11.021
   PubMed Web of Science ®Google Scholar
• Hardy GH. Mendelian proportions in a mixed population. Science. 1908;28(706):49–50. doi:10.1126/science.28.706.49
   PubMedGoogle Scholar
• Stark AE. A clarification of the Hardy-Weinberg law. Genetics. 2006;174:1695–1697.
   Web of Science ®Google Scholar
• Kobow K, Blümcke I. Epigenetics in epilepsy. Neurosci Lett. 2018;667:40–46. doi:10.1016/j.neulet.2017.01.012
   PubMed Web of Science ®Google Scholar
• Monostory K, Nagy A, Tóth K, et al. Relevance of CYP2C9 function in valproate therapy. Curr Neuropharmacol. 2019;17(1):99–106. doi:10.2174/1570159X15666171109143654
   PubMed Web of Science ®Google Scholar
• Morath B, Green K, Zaradzki M, Heid J, Karck M, Hoppe-Tichy T. Subtherapeutic valproic acid plasma concentrations under concomitant dipyrone therapy in an epilepsy patient-a case report. Eur J Clin Pharmacol. 2018;74(5):675–677. doi:10.1007/s00228-018-2417-5
   Web of Science ®Google Scholar